2021 American Transplant Congress
Impact of Cytomegalovirus Prophylaxis on Herpes Simplex and Varicella Zoster Virus Infections in Kidney Transplant Recipients
*Purpose: To assess the impact of cytomegalovirus (CMV) targeted antiviral prophylaxis on the development of herpes simplex (HSV) and varicella zoster (VZV) infections after kidney…2021 American Transplant Congress
Evaluation of High-versus Low-Dose Valganciclovir for Cytomegalovirus Prevention in Adult Liver Transplant Recipients: A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is the most common infection after solid organ transplantation and is associated with increased morbidity and mortality. CMV prophylaxis is widely considered…2021 American Transplant Congress
Significance of Detectable but Unquantifiable Viremias Post Renal Transplantation
Robert Wood Johnson University Hospital, New Brunswick, NJ
*Purpose: It is unknown whether the degree of the initial viremia following kidney (KT) or combined kidney-pancreas transplantation (SPKT) correlates with future allograft rejection or…2021 American Transplant Congress
Pregnancy After CMV Infection Following Uterus Transplantation: A Case Report
Abdominal Transplant Surgery, Baylor University Medical Center, Dallas, TX
*Purpose: Uterus transplantation (UTx) is a repeatedly proven treatment for women with absolute uterine factor infertility who wish to carry a pregnancy. One aspect of…2021 American Transplant Congress
Simulation Model for Cytomegalovirus Matching in Deceased Donor Kidney Allocation System in the U.S.
*Purpose: The prevalence of positive and negative cytomegalovirus (CMV) serology among transplant recipients and donors are approximately 60-65% and 30-35%, respectively. CMV mismatch, donor-positive/recipient-negative status…2021 American Transplant Congress
Cytomegalovirus Nephritis: Epidemiology and Outcomes of an Uncommon Diagnosis
Division of Nephrology, University of Wisconsin-Madison, Madison, WI
*Purpose: Cytomegalovirus (CMV) nephritis is an uncommon end-organ manifestation of CMV disease. Due to this, associated outcomes have not been completely elucidated.*Methods: This was a…2021 American Transplant Congress
Excellent Outcomes of Kidney Transplantation from Hepatitis C Infected Donors
UVA Health System, University of Virginia, Charlottesville, VA
*Purpose: Utilization of Hepatitis C viremic (HCV D+) kidney donors in HCV naïve recipients has increased in the United States. While there are shorter waiting…2021 American Transplant Congress
Economic and Clinical Benefit of Cmv Matching in Kidney Transplantation
*Purpose: Recently, kidney transplant (KTx) centers in Oregon collaborated to preferentially allocate cytomegalovirus-seronegative (CMV D-) kidneys to seronegative recipients (CMV R-), successfully reducing high-risk CMV…2021 American Transplant Congress
Changes in Cytomegalovirus Specific T Cell Immunity With Immunomodulation in Serodiscordant High Risk Transplant Recipients
Virginia Commonwealth University Health, Richmond, VA
*Purpose: Cytomegalovirus (CMV) infections cause significant morbidity and mortality among all solid organ transplant recipients. CMV discordant (D+/R-) recipients are at higher risk of developing…2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 33
- Next Page »